Paolo Tarantino Started New Role as Associate Editor for Breast Cancer at ESMO Open - OncoDaily Paolo Tarantino Started New Role as Associate Editor for Breast Cancer at ESMO Open / cancer, ESMO Open, OncoDaily, Oncology, Paolo Tarantino

Paolo Tarantino Started a New Role as Associate Editor for Breast Cancer at ESMO Open

@ptarantinomd.bsky.social @myesmo.bsky.social

oncodaily.com/career/paolo...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMOOpen

📢New publication alert!

Results from the EORTC-1560-GITCG (ILOC) phase II trial are now in #ESMOOpen.

The study assessed local ablative therapy + #immunotherapy in unresectable liver metastases from #colorectalcancer.

🔗Read more: www.eortc.org/bibliography/

#CancerResearch #EORTCgastrointestinal

The phase II FIGHT-202 trial’s final results reveal pemigatinib, a selective FGFR1-3 inhibitor, shows 37% ORR in patients with advanced/metastatic #CCA harboring #FGFR2 fusions/rearrangements (cohort A) 🌟

@myesmo.bsky.social #esmoopen

#Onco404 #Cancer #Kanser #Cholangiocarcinoma #Pemigatinib

Happy to share our recent #ESMOOpen paper on the #safety and #feasibility of #outpatient administration of #tarlatamab as part of the #DeLLphi300 study providing evidence that support less intensive monitoring at initiation of therapy. #LCSM 🫁 #SCLC 😀

doi.org/10.1016/j.es...

Oncology professionals’ perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series The European Society for Medical Oncology (ESMO) Resilience Task Force (RTF) was established to address burnout and well-being issues among oncology professionals. In this article, we present findings...

📝 We recently published the #ESMORTF position paper re: optimising well-being in the oncology workforce:
www.esmoopen.com/article/S205...

To supplement these recommendations, we have further detailed the qualitative data used in this piece - now out in #ESMOOpen 👇
www.esmoopen.com/article/S205...

DEFINE_ME

Just published in #ESMOopen results from our trial of IO-naive patients with advanced kidney cancer with PD1/CTLA4 and PD1/LAG3!

www.esmoopen.com/article/S205...

For further details of the above-referenced paper, this is available #OpenAccess at #ESMOOpen.

#ESMO4Carers

📰 This is based on lessons learned from >3,700 colleagues from >100 countries: a synthesis of recommendations to manage psychosocial risks at work:
www.esmoopen.com/article/S205...